GLAUCOMA
Conditions
Interventions
Palmytoilethanolamide (Visimast) oral admistration 300mg twice daily./ At baseline and the following examinations the following parameters were evaluated: best corrected visual acuity, biomicroscopic
Sponsors
UNIVERSITY OF CATANIA
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients aged 18-70 years, affected by primary open angle glaucoma with ocular hypertension under control with hypotonic drug (<18mmHg). 2. Visual field defects and optic disc cupping for at least one year (with at least 2 following exams). 3. All patients should be able to perform a reliable visual field (a minimum of 5 tests).
Exclusion criteria
Exclusion criteria: 1. Advanced stage glaucoma 2. Smokers 3. No tolerability to product under evaluation 4. Needs of glaucoma surgical or laser therapy 5. Ocular surgery in the last year 6. Visual acuity lower < 8/10 with refractive error > 3 diopters 7. Pupillary diameter < 2.5mm 8. Concomitant systemic or ocular pathologies 9. Pregnant or lactation 10. Vasoactive systemic therapies (Ca- antagonistis, oral betablokers, others) 11 Partecipation to other trials
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluate the role of Palmitoylethanolamide (PEA) to reduce Intraocular Pressure value in patients with ocular hypertension (OHT) and primary open angle glaucoma (POAG). | — |
Secondary
| Measure | Time frame |
|---|---|
| Evaluate visual acuity, visual fields, vital signs and psycotropic effects. | — |
Countries
Europe
Contacts
Public ContactCATERINA GAGLIANO
UNIVERSITY OF CATANIA OPHTHALMOLOGY DEPERTMENT
Outcome results
None listed